lepzacitinib   Click here for help

GtoPdb Ligand ID: 12871

Synonyms: example 117 [WO2019090158A1]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The structure for lepzacitinib was obtained from proposed INN list 129 (August 2023) where it is described as a Janus kinase inhibitor and anti-inflammatory agent. It is one of the compounds claimed in patent WO2019090158A1 [1]. Aclaris have three JAK inhibitors in their development pipeline, two of which are in clinical assessment: ATI-1777 (a soft inhibitor for topical applications such as atopic dermatitis), and ATI-2138 (a dual ITK/JAK3) inhibitor for T cell-mediated autoimmune diseases. Lepzacitinib is most likely ATI-1777.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 106.82
Molecular weight 355.39
XLogP 0.53
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCOC(=O)C1=C(C2=C(NC=C2)N=C1)N[C@@H]3CCCN(C3)C(=O)CC#N
Isomeric SMILES C(#N)CC(=O)N1C[C@@H](CCC1)NC2=C3C(=NC=C2C(=O)OCC)NC=C3
InChI InChI=1S/C18H21N5O3/c1-2-26-18(25)14-10-21-17-13(6-8-20-17)16(14)22-12-4-3-9-23(11-12)15(24)5-7-19/h6,8,10,12H,2-5,9,11H2,1H3,(H2,20,21,22)/t12-/m1/s1
InChI Key QQOPOYMFJLUSBI-GFCCVEGCSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
ATI-1777 has advanced to clinical evaluations and will be tested for effecacy as a topically applied agent for atopic dermatitis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04598269 Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2 Interventional Aclaris Therapeutics, Inc.
NCT05432596 Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis Phase 2 Interventional Aclaris Therapeutics, Inc.